| NCT ID | NCT07311434 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Athletic Greens International |
| Condition | Sleep |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2026-01-20 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will be a prospective randomized, controlled clinical study. There will be interventional treatment for a total of 30 days. The subjects will complete questionnaires throughout the study at pre-specified timepoints.
Eligibility Criteria
Inclusion Criteria: * Male or female. * Age 25-59 years. * BMI ≥18.5 and ≤29.9 kg/m². * Currently experiencing issues with sleep quality, falling asleep, staying asleep, or waking during the night. * RU-SATED score ≤17. * Willing and able to follow the study protocol. * Willing to discontinue any other supplements (including nootropics, adaptogens, calming herbs), medications, herbal remedies, or over-the-counter sleep medications (e.g., zolpidem, diphenhydramine, Benadryl, ZzzQuil, Unisom, magnesium or melatonin products) used to assist with sleep during the study. * Agree to limit alcohol intake within approximately 4 hours of bedtime throughout participation. * Agree to limit caffeine intake to ≤400 mg/day (about 3-4 cups of coffee) and avoid ingestion of caffeine-containing products after 2:00 PM during the study period. * Generally healthy and not living with any uncontrolled chronic disease. * Resides in the United States. * Willing to discontinue any restricted products and adhere to all required study assessments. Exclusion Criteria: * Diagnosed chronic sleep conditions (e.g., insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome, sleep apnea). * Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception. Women currently undergoing perimenopause or experiencing vasomotor symptoms (e.g., night sweats). * Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months. * Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares. * Diagnosed neurodegenerative or chronic pain disorders, including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia. * Regular prescribed stimulant use (e.g., amphetamines such as Adderall/Vyvanse; methylphenidate such as Ritalin/Concerta; modafinil/armodafinil). * Current use of CNS-activating antidepressants (bupropion, fluoxetine, venlafaxine, sertraline). * Current or recent use of cannabis or THC-containing products (recreational or medicinal marijuana, CBD with measurable THC, synthetic cannabinoids) within the past 30 days. * Employment in jobs disrupting nighttime sleep (e.g., night shift, rotating shift, excessive travel). * Current use of prescription sleep aids. * Introduction of any new sleep-related supplements, medications, herbal remedies, or melatonin products during the study. * Use of any prescription or OTC products with sedative properties (e.g., melatonin, diphenhydramine, doxylamine, valerian, ZzzQuil, Advil PM) within 4 weeks prior to enrollment or habitual use ≥3 times per week prior to enrollment unless investigator-approved. * Allergy or sensitivity to any study product ingredients. * Pregnant, breastfeeding, or trying to conceive during the study period. * History of substance abuse. * Heavy alcohol use (≥8 drinks/week for women or ≥15 drinks/week for men). * Participation in another research study now or within the next 7 weeks. * Any condition or behavior that, in the investigator's judgment, may interfere with study participation or data integrity.
Contact & Investigator
Philip Sapp, PhD, MS
PRINCIPAL INVESTIGATOR
Athletic Greens - AG1
Frequently Asked Questions
Who can join the NCT07311434 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 59 Years, studying Sleep. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07311434 currently recruiting?
Yes, NCT07311434 is actively recruiting participants. Visit ClinicalTrials.gov or contact Athletic Greens International to inquire about joining.
Where is the NCT07311434 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07311434 clinical trial?
NCT07311434 is sponsored by Athletic Greens International. The principal investigator is Philip Sapp, PhD, MS at Athletic Greens - AG1. The trial plans to enroll 300 participants.